Nano-X Imaging (NNOX) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
13 Mar, 2026Company overview and business model
Focuses on making diagnostic medicine more accessible and affordable globally through proprietary medical imaging technology and solutions, including the Nanox System (Nanox.ARC hardware and Nanox.CLOUD software), AI imaging solutions, healthcare IT, and teleradiology services.
Nanox System leverages a novel digital MEMS X-ray source, aiming to disrupt legacy X-ray and CT imaging by reducing costs and complexity.
Business model includes modular and end-to-end imaging solutions, with a hybrid approach in the U.S. (usage-based MSaaS and CapEx) and CapEx-focused sales in the EU.
Offers AI-based population health solutions, teleradiology, and a decentralized marketplace for remote imaging interpretation.
Financial performance and metrics
As of December 31, 2025, 69,590,228 ordinary shares were issued and outstanding.
The company has never declared or paid cash dividends on its ordinary shares.
Financial statements and internal control effectiveness are audited by Kesselman & Kesselman, a member of PwC.
Use of proceeds and capital allocation
Net proceeds from securities sales will be used for research funding, general corporate purposes, commercial efforts, acquisitions, working capital, and capital expenditures.
Management has broad discretion over allocation of proceeds.
Latest events from Nano-X Imaging
- Q4 2024 revenue reached $3.0M, but net loss increased to $14.1M as expansion accelerated.NNOX
Q4 202417 Mar 2026 - Revenue up to $2.8M, net loss widens, over 60 ARC units deployed, FDA clearance boosts outlook.NNOX
Q1 202517 Mar 2026 - Q2 2025 revenue rose to $3.0M, net loss increased to $14.7M, and 100+ installations targeted.NNOX
Q2 202517 Mar 2026 - Expanded deployments, new FDA clearances, and improved financials mark a strong Q2 2024.NNOX
Q2 202423 Jan 2026 - 3D X-ray imaging with AI and cloud updates drives global growth and access in medical imaging.NNOX
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Q3 2024 saw $3.0M revenue, narrowed net loss, and strong teleradiology and AI growth.NNOX
Q3 202412 Jan 2026 - Mobile 3D imaging and AI tools drive commercial growth and strong market interest.NNOX
Sidoti's Year End Virtual Investor Conference12 Dec 2025 - Q3 2025 revenue reached $3.4M; VasoHealthcare IT deal and global growth drive 2026 outlook.NNOX
Q3 202520 Nov 2025 - Innovative 3D imaging system with AI gains regulatory clearance and begins global rollout.NNOX
Q2 Virtual Investor Summit Event13 Nov 2025